Oculis to Host In-Person and Virtual R&D Day
Oculis Holding AG (NASDAQ: OCS / XICE: OCS), a pioneering biopharmaceutical company dedicated to addressing significant unmet needs in the field of ophthalmic and neuro-ophthalmic diseases, is excited to announce an upcoming event. The company will hold an innovative R&D Day on the 15th of the month from 10:00 AM to 12:00 PM ET. This special event will cater to both in-person attendees and online participants, hosted at a notable venue in New York.
Focus on Clinical Development and Business Strategies
During the R&D Day, Oculis plans to provide comprehensive updates regarding its dynamic portfolio of late-stage clinical candidates. Attendees can look forward to essential discussions on recent clinical data and future development strategies, which will include insights into ongoing projects and business direction. Experts in the field will present their insights, ensuring that the attendees are well-informed about the latest advancements and future potential.
Key Opinion Leaders Attending
Among the distinguished speakers will be numerous key opinion leaders (KOLs) specializing in various fields:
- Retina Specialists:
- Dr. David Boyer, a renowned figure from the Keck School of Medicine, University of Southern California.
- Dr. Arshad Khanani, affiliated with the Reno School of Medicine, University of Nevada.
- Dr. Baruch D. Kuppermann from the University of California, Irvine.
- Dr. Sebastian Wolf from the Department of Ophthalmology at the University of Bern.
- Inflammation and Precision Medicine:
- Dr. Anat Galor from the Bascom Palmer Eye Institute, University of Miami.
- Neuro-Ophthalmology Experts:
- Dr. Mark Kupersmith from Mount Sinai.
- Dr. Leonard Levin from McGill University.
- Dr. Pablo Villoslada from Stanford University and Hospital del Mar.
Innovations in Eye Treatment
The presentations will delve into the progress of Phase 3 trials for OCS-01 eye drops, aimed at treating diabetic macular edema (DME), and discuss the future of Licaminlimab (OCS-02) in treating dry eye disease (DED). A particular focus will be on Privosegtor (OCS-05), which shows promise for treating acute optic neuritis and related conditions.
Understanding Privosegtor (OCS-05)
Privosegtor (OCS-05) is a cutting-edge small molecule therapy currently under investigation for its neuroprotective properties. Recent trial results suggest that this innovative treatment could lead to significant improvements in patient outcomes for those suffering from acute optic neuritis. The therapeutic candidate has shown potential not only for neuroprotection but also for enhancing visual function.
Clinical Insights from Trials
The positive outcomes of the ACUITY Phase 2 trial indicate that Privosegtor is effective in preserving retinal health and restoring vision. Such advancements arguably mark a breakthrough in our understanding of how to manage neuro-ophthalmologic disorders.
Comprehensive Approach to Eye Health
Oculis maintains a commitment to innovation, reflected in its broad pipeline designed to tackle various eye health issues. The range includes OCS-01 for DME, Licaminlimab (OCS-02) targeting DED, and now, the promising prospects associated with Privosegtor (OCS-05). The company’s strategic vision focuses on maximizing the clinical development of these therapies to improve patient care.
Commitment to Patient-Centric Solutions
As Oculis continues to shape the future of eye care, patient safety, and accessibility remain top priorities. With each incremental development, the impact on patients and their families is profoundly understood and pursued.
Frequently Asked Questions
What is the purpose of the R&D Day hosted by Oculis?
The R&D Day is designed to provide updates on Oculis' clinical candidates and discuss future development plans and business strategies.
Who are some of the key speakers at the event?
Notable speakers include Dr. David Boyer, Dr. Arshad Khanani, and Dr. Anat Galor, among others.
What is Privosegtor (OCS-05) intended to treat?
Privosegtor is being studied for its neuroprotective effects on acute optic neuritis and other neuro-ophthalmic conditions.
What are the current developments in Omos-01?
OCS-01 is advancing through Phase 3 trials, targeting therapies for diabetic macular edema.
How does Oculis plan to improve patient care?
Oculis aims to maximize the potential of its innovative therapies, ensuring safe and effective treatments for eye health concerns.
